135 related articles for article (PubMed ID: 2854011)
1. Serum pseudouridine as a biochemical marker in patients with hepatocellular carcinoma.
Amuro Y; Nakaoka H; Shimomura S; Fujikura M; Yamamoto T; Tamura S; Hada T; Higashino K
Clin Chim Acta; 1988 Dec; 178(2):151-8. PubMed ID: 2854011
[TBL] [Abstract][Full Text] [Related]
2. Urinary excretion of pseudouridine in patients with hepatocellular carcinoma.
Tamura S; Amuro Y; Nakano T; Fujii J; Moriwaki Y; Yamamoto T; Hada T; Higashino K
Cancer; 1986 Apr; 57(8):1571-5. PubMed ID: 2418945
[TBL] [Abstract][Full Text] [Related]
3. Urinary pseudouridine as a biochemical marker in the diagnosis and monitoring of primary hepatocellular carcinoma.
Tamura S; Fujioka H; Nakano T; Amuro Y; Hada T; Nakao N; Higashino K
Am J Gastroenterol; 1988 Aug; 83(8):841-5. PubMed ID: 2456010
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of urinary and serum pseudouridine in diagnosis and monitoring of primary liver cancer.
Tu Z; Xu S; Wu M
Chin Med J (Engl); 1995 Mar; 108(3):204-8. PubMed ID: 7796629
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
Jia X; Gao Y; Zhai D; Liu J; Cai J; Wang Y; Jing L; Du Z
Technol Cancer Res Treat; 2016 Dec; 15(6):780-786. PubMed ID: 26370140
[TBL] [Abstract][Full Text] [Related]
6. Serum pseudouridine as a biochemical marker in small cell lung cancer.
Tamura S; Fujioka H; Nakano T; Hada T; Higashino K
Cancer Res; 1987 Nov; 47(22):6138-41. PubMed ID: 2822241
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of a monoclonal antibody to serum KM01 for the diagnosis of hepatocellular carcinoma.
Fujii T; Horie Y; Ikuta Y; Nishimuki E; Murawaki Y; Suou T; Kawasaki H
Clin Chim Acta; 1995 Apr; 236(1):71-9. PubMed ID: 7545092
[TBL] [Abstract][Full Text] [Related]
8. Boronate affinity chromatography of gamma-glutamyltransferase in patients with hepatocellular carcinoma.
Yamamoto T; Amuro Y; Matsuda Y; Nakaoka H; Shimomura S; Hada T; Higashino K
Am J Gastroenterol; 1991 Apr; 86(4):495-9. PubMed ID: 1707223
[TBL] [Abstract][Full Text] [Related]
9. Serum alpha-L-fucosidase activity and early detection of hepatocellular carcinoma: a prospective study of patients with cirrhosis.
Giardina MG; Matarazzo M; Morante R; Lucariello A; Varriale A; Guardasole V; De Marco G
Cancer; 1998 Dec; 83(12):2468-74. PubMed ID: 9874450
[TBL] [Abstract][Full Text] [Related]
10. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein.
Iacovazzi PA; Trisolini A; Barletta D; Elba S; Manghisi OG; Correale M
Clin Chem Lab Med; 2001 Oct; 39(10):961-5. PubMed ID: 11758611
[TBL] [Abstract][Full Text] [Related]
11. Pseudouridine determination in blood serum as tumor marker.
Salvatore F; Russo T; Colonna A; Cimino L; Mazzacca G; Cimino F
Cancer Detect Prev; 1983; 6(6):531-6. PubMed ID: 6318996
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of hepatocellular carcinoma by concanavalin A affinity electrophoresis of serum alpha-fetoprotein.
Saitoh S; Ikeda K; Koida I; Suzuki Y; Kobayashi M; Tsubota A; Arase Y; Chayama K; Murashima N; Kumada H
Cancer; 1995 Oct; 76(7):1139-44. PubMed ID: 8630889
[TBL] [Abstract][Full Text] [Related]
13. [Usefulness of serum alpha-fetoprotein (AFP) as a marker for hepatocellular carcinoma (HCC) in hepatitis C virus related cirrhosis: analysis of the factors influencing AFP elevation without HCC development].
Kim KA; Lee JS; Jung ES; Kim JY; Bae WK; Kim NH; Moon YS
Korean J Gastroenterol; 2006 Nov; 48(5):321-6. PubMed ID: 17132920
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
[TBL] [Abstract][Full Text] [Related]
15. Serum alpha-L-fucosidase. A useful marker in the diagnosis of hepatocellular carcinoma.
Giardina MG; Matarazzo M; Varriale A; Morante R; Napoli A; Martino R
Cancer; 1992 Sep; 70(5):1044-8. PubMed ID: 1381268
[TBL] [Abstract][Full Text] [Related]
16. Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis.
Fabris C; Basso DA; Leandro G; Meggiato T; Elba S; Panozzo MP; Del Favero G; Fogar P; Di Mario F; Naccarato R
Cancer; 1991 Oct; 68(8):1795-8. PubMed ID: 1717126
[TBL] [Abstract][Full Text] [Related]
17. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis.
Arrieta O; Cacho B; Morales-Espinosa D; Ruelas-Villavicencio A; Flores-Estrada D; Hernández-Pedro N
BMC Cancer; 2007 Feb; 7():28. PubMed ID: 17288606
[TBL] [Abstract][Full Text] [Related]
18. Serum biomarkers for early detection of hepatocellular carcinoma associated with HCV infection in egyptian patients.
Zekri AR; Youssef AS; Bakr YM; Gabr RM; El-Rouby MN; Hammad I; Ahmed EA; Marzouk HA; Nabil MM; Hamed HA; Aly YH; Zachariah KS; Esmat G
Asian Pac J Cancer Prev; 2015; 16(3):1281-7. PubMed ID: 25735368
[TBL] [Abstract][Full Text] [Related]
19. Urinary pseudouridine as a tumor marker in patients with small cell lung cancer.
Tamura S; Fujii J; Nakano T; Hada T; Higashino K
Clin Chim Acta; 1986 Jan; 154(2):125-32. PubMed ID: 3006946
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
